- Home
- CNX vs IOVA Comparison
CNX vs IOVA Comparison
Compare CNX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- IOVA
- Stock Information
- Founded
- CNX 1860
- IOVA 2007
- Country
- CNX United States
- IOVA United States
- Employees
- CNX N/A
- IOVA N/A
- Industry
- CNX Oil & Gas Production
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNX Energy
- IOVA Health Care
- Exchange
- CNX Nasdaq
- IOVA Nasdaq
- Market Cap
- CNX 4.6B
- IOVA 771.4M
- IPO Year
- CNX 1999
- IOVA N/A
- Fundamental
- Price
- CNX $34.15
- IOVA $1.71
- Analyst Decision
- CNX Hold
- IOVA Buy
- Analyst Count
- CNX 13
- IOVA 10
- Target Price
- CNX $31.83
- IOVA $12.22
- AVG Volume (30 Days)
- CNX 2.2M
- IOVA 11.8M
- Earning Date
- CNX 07-24-2025
- IOVA 08-07-2025
- Dividend Yield
- CNX N/A
- IOVA N/A
- EPS Growth
- CNX N/A
- IOVA N/A
- EPS
- CNX N/A
- IOVA N/A
- Revenue
- CNX $1,579,627,000.00
- IOVA $212,679,000.00
- Revenue This Year
- CNX $25.79
- IOVA $86.62
- Revenue Next Year
- CNX $24.57
- IOVA $69.95
- P/E Ratio
- CNX N/A
- IOVA N/A
- Revenue Growth
- CNX 19.15
- IOVA 11070.12
- 52 Week Low
- CNX $23.85
- IOVA $1.64
- 52 Week High
- CNX $41.93
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- CNX 56.77
- IOVA 36.89
- Support Level
- CNX $31.26
- IOVA $1.95
- Resistance Level
- CNX $35.05
- IOVA $2.47
- Average True Range (ATR)
- CNX 0.93
- IOVA 0.16
- MACD
- CNX 0.09
- IOVA -0.00
- Stochastic Oscillator
- CNX 62.06
- IOVA 6.41
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.